IJTLD Open (ISSN: 3005-7590) is open access and fully compliant with Plan S.
IJTLD Open includes a broader range of article types than the traditional IJTLD, including: Editorials, Meeting reports, Original Articles (including methodology papers, qualitative research and operational research), State of the Art Reviews, Guidelines/Consensus documents, Systematic Reviews and Meta-Analysis, Perspectives, Minireviews, Letters, Case reports, Case series and Correspondence.
We publish high impact research for the continuing education of academics, clinicians and all other health personnel working on respiratory diseases and lung health, with the aim of improving policy and practise.
IJTLD OPEN is open access and free to read. Also, authors retain copyright and can freely distribute the PDF or upload it to any website. As a consequence, open access articles are highly downloaded and more highly cited.
Click the links below to read our content on PubMed Central, Ingenta.com or via links from the Directory of Open Access Journals (DOAJ), or PubMed. .
While preparing their article, authors should refer to the Instructions for Authors to check that they have complied with our requirements – see links below.
Once complete, authors should submit their manuscripts at http://mc.manuscriptcentral.com/ijtld
We invite authors with OA funding to submit their papers (including Editorials, Original Articles, Letters and Case Series) to IJTLD OPEN.
We welcome submissions on the development of vaccines, diagnostics and medicines for the prevention, management and control of TB and all other respiratory diseases.
This includes basic, translational, clinical, epidemiological and programmatic research relevant to the Union’s mission to find health solutions for these conditions.
For all queries please e-mail the Editorial Office
Sponsorship
Supplements and article series are a highly-effective way of highlighting a specific topic to researchers, clinicians and decision makers in respiratory health.
Being an Open Access journal, IJTLD OPEN has no barriers to access and can reach readers in health centres, medical, university and pharmaceutical institutes, along with civil society, patients and carers.
All content will be freely available on Ingenta.com and we will have regular mailings to highlight the latest sponsored content.
Fast-Track Articles
In order to share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain accepted articles from the IJTLD, IJTLD OPEN and PHA and publishing them in full on our website, prior to their publication in the Journals. Read fast-track articles:
Asymptomatic COVID-19 – implications for the control of transmission in South Africa
The authors conducted a retrospective analysis to determine the proportion of asymptomatic COVID-19 in the workplace during lockdown in early 2020. Nearly 45% of cases were asymptomatic, which has implications for interventions, such as enforcing quarantine of all close contacts of COVID-19 cases regardless of symptoms.
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
In this recently accepted article for IJTLD, the authors performed a cohort-comparison study to assess Pretomanid in a regimen to treat drug-resistant TB: patients receiving the BPaL regimen had a significantly better 6-month post-treatment outcome than those on the B–L regimen. The preprint is free to read.
The impact of COVID-19 on TB: a review of the data
In this recently accepted Review for IJTLD, the authors summarise the evidence available at a country level, identifying broad mechanisms by which COVID-19 may modify TB burden and mitigation efforts.